A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the developmen...

Full description

Bibliographic Details
Main Authors: Ozhan Ocal, Victor Pashkov, Rahul K. Kollipara, Yalda Zolghadri, Victoria H. Cruz, Michael A. Hale, Blake R. Heath, Alex B. Artyukhin, Alana L. Christie, Pantelis Tsoulfas, James B. Lorens, Galvin H. Swift, Rolf A. Brekken, Thomas M. Wilkie
Format: Article
Language:English
Published: The Company of Biologists 2015-10-01
Series:Disease Models & Mechanisms
Subjects:
Rgs16::GFP reporter
Kras
Rapid in vivo screen
Pancreatic cancer combination therapy
Gas6
Axl
Warfarin
Gemcitabine
Abraxane
Online Access:http://dmm.biologists.org/content/8/10/1201

Internet

http://dmm.biologists.org/content/8/10/1201

Similar Items